Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PROF 
Profound Medical Corp (PROF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PROF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.1
1 Year Target Price $12.1
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.91% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 136.14M USD | Price to earnings Ratio - | 1Y Target Price 12.1 |
Price to earnings Ratio - | 1Y Target Price 12.1 | ||
Volume (30-day avg) 5 | Beta 0.3 | 52 Weeks Range 3.90 - 9.17 | Updated Date 08/28/2025 |
52 Weeks Range 3.90 - 9.17 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.27 | Actual 0.52 |
Profitability
Profit Margin - | Operating Margin (TTM) -624.42% |
Management Effectiveness
Return on Assets (TTM) -53.05% | Return on Equity (TTM) -103.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 104480931 | Price to Sales(TTM) 11.5 |
Enterprise Value 104480931 | Price to Sales(TTM) 11.5 | ||
Enterprise Value to Revenue 8.82 | Enterprise Value to EBITDA -5.75 | Shares Outstanding 30053100 | Shares Floating 27569550 |
Shares Outstanding 30053100 | Shares Floating 27569550 | ||
Percent Insiders 17.35 | Percent Institutions 45.98 |
Upturn AI SWOT
Profound Medical Corp
Company Overview
History and Background
Profound Medical Corp. is a medical technology company focused on developing and commercializing customizable, incision-free therapies for localized diseases. Founded in 2008, the company has evolved from its initial focus on MRI-guided ultrasound technology to a broader platform addressing unmet needs in prostate and other disease states.
Core Business Areas
- Prostate Ablation: Developing and commercializing TULSA-PRO, a transurethral ultrasound ablation technology for prostate tissue. This segment is their primary focus.
- Research and Development: Ongoing research into expanding the application of their technology to other disease areas beyond prostate cancer.
Leadership and Structure
The company is led by a management team with experience in medical device development and commercialization. Organizational structure typically includes departments for R&D, clinical affairs, sales, marketing, and operations. Specifics on exact individuals are not available without real-time data.
Top Products and Market Share
Key Offerings
- TULSA-PRO: TULSA-PRO is Profound Medical's primary product, utilizing MRI-guided transurethral ultrasound ablation to precisely ablate prostate tissue. Market share data is difficult to ascertain precisely as it's an emerging market, but Profound is a key player. Competitors include companies offering HIFU (High-Intensity Focused Ultrasound) and other minimally invasive prostate cancer treatments like cryoablation and radiation therapy. Key players include EDAP TMS (EDAP) with HIFU, and SonaCare Medical. Revenue specifics require up-to-date financial information.
Market Dynamics
Industry Overview
The market for prostate cancer treatment is characterized by a growing aging population and increased awareness of minimally invasive treatment options. The trend favors precision therapies with fewer side effects than traditional surgery or radiation.
Positioning
Profound Medical is positioned as a provider of precise, customizable prostate ablation therapy with the potential for reduced side effects compared to traditional treatments. Their competitive advantage lies in the real-time MRI guidance and precise ablation capabilities of TULSA-PRO.
Total Addressable Market (TAM)
TAM for prostate cancer treatment is estimated to be billions of dollars annually, encompassing various therapies. Profound Medical aims to capture a significant portion of this market by offering a compelling alternative to existing treatment modalities.
Upturn SWOT Analysis
Strengths
- Precise ablation technology
- MRI-guided real-time monitoring
- Minimally invasive approach
- Potential for reduced side effects
- Growing body of clinical evidence
Weaknesses
- Limited commercialization experience
- Reliance on a single product
- Relatively small company size
- Requires specialized equipment and training
- Market adoption dependent on physician acceptance
Opportunities
- Expanding applications to other disease states
- Gaining regulatory approvals in new markets
- Partnering with hospitals and clinics
- Increasing awareness among patients and physicians
- Developing next-generation technology
Threats
- Competition from established players
- Reimbursement challenges
- Technological advancements by competitors
- Adverse clinical outcomes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- EDAP
- SONA
Competitive Landscape
Profound Medical competes primarily with other minimally invasive prostate cancer treatment options. Their advantage is TULSA-PRO's precision, but they face challenges from established companies with broader product portfolios and larger installed bases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be based on revenue and product adoption data. Information is available on financial news websites. These would need to be updated dynamically.
Future Projections: Future growth projections are based on analyst estimates and company guidance and will vary across sources.
Recent Initiatives: Recent initiatives are typically focused on expanding the commercial reach of TULSA-PRO and pursuing regulatory approvals in new markets. Access to press releases and investor relations materials would provide concrete examples.
Summary
Profound Medical Corp. is a growing medical technology company focused on minimally invasive prostate cancer treatment. Their TULSA-PRO technology shows promise, but the company faces challenges related to commercialization and competition. Future success depends on gaining broader market adoption and expanding into new applications and markets. Monitoring their financials and how they are addressing their competitive advantages is key to following the company's trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Providers
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data is subject to change and requires accessing real-time sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Profound Medical Corp
Exchange NASDAQ | Headquaters Mississauga, ON, Canada | ||
IPO Launch date 2016-06-09 | Chairman of the Board & CEO Dr. Arun Swarup Menawat MBA, Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 142 | Website https://www.profoundmedical.com |
Full time employees 142 | Website https://www.profoundmedical.com | ||
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.